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ABSTRACT
Background/aims New antibiotic agents and
changing susceptibility patterns may have changed the
empirical treatment of bacterial keratitis. Our objective
in this study was to survey cornea specialists’ practice
patterns in the initial treatment of bacterial ulcers.
Methods This study consisted of a short online
survey emailed to members of the Cornea Society
listserv for an international sample of cornea
specialists. Data collection began July 2014 and ended
October 2014.
Results A total of 1009 surveys were emailed, and we
received 140 (14%) responses. The majority of US
clinicians surveyed (n=83, 80%) chose fortified
antibiotics empirically, with 55% (n=57) selecting
fortified vancomycin and 16% (n=17) using
fluoroquinolone alone. International respondents were
twice as likely to use fluoroquinolone monotherapy
(31%, n=11, p=0.07) and less likely to use fortified
vancomycin (33%, n=12, p=0.03). Forty-five per cent
(n=46) of US respondents reported that their initial
antibiotic choice covered methicillin-resistant
Staphylococcus aureus, compared with 22% (n=8) of
international respondents (p<0.01). Overall,
respondents who were concerned about availability of
antibiotics and toxicity were 20.86 (p<0.001) and 7.48
(p<0.001) times more likely to choose fluoroquinolone
monotherapy, respectively. If respondents’ primary
considerations were broad spectrum coverage or
antibiotic resistance they had 7.10 (p<0.001) and
12.51 (p<0.001) times the odds of using fortified
vancomycin, respectively.
Conclusion Practice patterns for the initial treatment
of bacterial keratitis vary with clinicians in the USA
being more likely to use fortified antibiotics versus
fluoroquinolone monotherapy and more concerned
with resistant organisms than their international peers.
INTRODUCTION
In the literature and at our own institution,
there has been debate about the use of
commercially available fourth-generation
fluoroquinolones versus compounded forti-
fied antibiotics such as vancomycin and
tobramycin for the initial treatment of
bacterial corneal ulcers. Determining the
best treatment depends on the causative
organism; however, Gram stain and culture
results are not available for hours to days,
and initial therapy is commonly empirical.
Several randomised controlled trials have
shown equivalency between the fluoroquino-
lones and fortified antibiotics.1–5 In the
recent Steroids for Corneal Ulcer Trial, no
bacteria were resistant to moxifloxacin.6
Despite this, the use of fortified antibiotics
remains quite common.7 8 Of note, most of
these studies occurred in developing coun-
tries where bacterial resistance patterns are
likely to be quite different from the those in
developed countries such as the USA.
New antibiotic agents, such as topical line-
zolid, and changing susceptibility patterns
may have altered the empirical treatment of
bacterial keratitis.9 Here we assess corneal
specialists’ current practice patterns
regarding initial treatment of severe central
bacterial ulcers.
MATERIALS AND METHODS
An international survey was distributed via
email to members of the Cornea Society list-
serv. Participation was completely voluntary
and anonymous, and no identifiers were
collected including name, age or sex. The
survey was initially distributed on 21 July
Key messages
" There is debate over the best empirical
treatment for bacterial keratitis, and there are
regional variations in practice patterns of
corneal specialists.
" This survey demonstrates that practice patterns
are influenced by concern over availability
and toxicity versus broad spectrum coverage
and resistance. Overall, respondents in the
USA were more likely to treat with fortified
antibiotics than their international peers.
" A well-designed clinical trial on the treatment of
bacterial ulcers is needed to help
clinicians initiate the best treatment and
ultimately reduce morbidity.
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2014 via the internet survey tool SurveyMonkey
(surveymonkey.com; Palo Alto, California), with one
reminder on 26 August 2014. Data collection was
closed in October of 2014.
The survey consisted of seven questions (figure 1).
Respondents were presented with the clinical scenario
of a patient with a large, central, bacterial corneal ulcer
and were asked what their empirical antibiotic treat-
ment would be, why they chose that regimen and
whether they would obtain cultures prior to instituting
treatment. Specific antibiotic regimens given as options
included fourth-generation fluoroquinolones (such as
moxifloxacin and gatifloxacin) and fortified antibiotics
(including tobramycin, vancomycin and cefazolin).
Respondents were also queried regarding their demo-
graphics including their geographic location, the
average number of corneal ulcers seen per month as
well as the number of years they had been in practice.
Finally they were asked what percentage of Staphylo-
coccus aureus in the community would have to be
methicillin-resistant Staphylococcus aureus (MRSA) for
them to cover MRSA empirically.
Responses were collected and analysed using descrip-
tive statistics with Stata V.14.0. 2 test was used to
compare responses between international and US
respondents, and logistic regression models were used
to assess the relationship between specific concerns,
such as toxicity or antibiotic resistance and choice of
antibiotic. Institutional review board exemption was
obtained from the University of California, San
Francisco Committee on Human Research. The study
adhered to the Declaration of Helsinki and all federal
and state laws.
RESULTS
A total of 1009 cornea specialists were members at the
time the survey was sent out. One hundred forty
responses to the survey were received, for a response
rate of 14%. Respondents were mostly from the USA
(n=104), with the remaining international respondents
(n=36) coming from 17 countries on six continents
(table 1). Many respondents had greater than 20 years
of clinical experience (n=62, 44%), followed by
10–20 years in practice (n=33, 24%), 5–10 years in
practice (n=30, 21%) and 0–5 years in practice (n=15,
11%). In general, the international respondents
encountered more cases of infectious keratitis per
month, with 42% seeing more than five cases per
month versus 24% of US respondents (p=0.05). When
asked if they would culture a large central ulcer, all
international respondents (n=36) and 98% (n=101) of
US respondents reported that they would (two US
respondents, or 2%, said they would not).
Respondents were asked about their empirical treat-
ment of bacterial keratitis, and their responses
revealed marked differences in practice patterns
between clinicians in the USA and in other countries,
as seen in figure 2. In the USA, the majority of
Figure 1 Survey distributed to corneal specialists via email.
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clinicians surveyed (n=83, 80%) chose fortified antibi-
otics as their initial treatment, with 55% (n=57)
choosing fortified vancomycin. Sixteen per cent
(n=17) of US clinicians surveyed chose to initially treat
with fourth-generation fluoroquinolones alone. Inter-
national respondents were twice as likely to use
fluoroquinolone monotherapy (31%, n=11, p=0.07)
and were less likely to use fortified vancomycin with
33% reporting it as their empirical choice (n=12,
p=0.03).
Reasons for selecting their chosen initial antibiotic
were largely similar across US and international sites.
Clinicians reported desiring broad-spectrum antibiotic
coverage most often, with 78% (n=81) of US respond-
ents and 89% (n=32) of international respondents
citing this as a reason for their antibiotic choice. Both
groups also reported the following reasons with similar
frequency: most effective (n=43, 41% US vs n=15,
42% internationally), availability (n=33, 32% US vs
n=12, 33% internationally), synergy (n=15, 14% US vs
n=6, 17% internationally) and toxicity profile (n=13,
13% US vs n=5, 14% internationally). US respondents
were more concerned about covering resistant organ-
isms, listing this as a reason for their empirical
antibiotic choice more than twice as often as interna-
tional respondents (n=41, 39% vs n=7, 19%, p=0.03).
Forty-five per cent (n=46) of US respondents
reported that their empirical antibiotic regimen
covered MRSA, compared with 22% (n=8) of interna-
tional respondents. Table 2 contrasts US and
international clinicians’ threshold for empirical MRSA
coverage, showing that international clinicians had a
lower threshold for empirical MRSA coverage than did
US clinicians (p<0.01).
Table 3 shows the relationship between the different
reasons for choosing a particular antibiotic and the
likelihood of selecting fluoroquinolone monotherapy
or fortified vancomycin, correcting for location
(defined as US or international). Respondents who
listed availability as a primary consideration had 20.86
times the odds of choosing fluoroquinolone mono-
therapy (p<0.001). Concern over ocular surface
toxicity was also predictive of choosing fluoroquinolone
monotherapy (OR=7.48, p<0.001). Not surprisingly,
respondents concerned about resistance had 12.51
times the odds of choosing fortified vancomycin
(p<0.001), while broad spectrum coverage was also a
statistically significant predictor for selecting vanco-
mycin (OR=7.10, p<0.001).
DISCUSSION
In this study, we report the results of an international
survey of cornea specialists regarding their empirical
treatment of large central corneal ulcers. We found
that practice patterns differ between US and interna-
tional sites, with US clinicians more likely to use
fortified antibiotics as their initial treatment. They
were also approximately twice as likely to use fortified
vancomycin empirically. Prior surveys have found that
cornea specialists are more likely than general ophthal-
mologists to treat bacterial keratitis with fortified
antibiotics.7 10 US respondents were more concerned
about resistant organisms and also more likely to
include coverage for MRSA in their default treatment.
Concern about the availability of antibiotics was the
greatest predictor of fluoroquinolone monotherapy.
Fortified antibiotics require a compounding phar-
macy and can be difficult for clinicians to access.
Table 1 Geographic distribution of respondentsl
Country N=140 (%)
USA* 104 (74)
Northeast 11 (11)
South 36 (35)
Midwest 22 (21)
West 33 (32)
Unknown 2 (2)
International 36 (26)
Armenia 1 (3)
Australia 2 (6)
Brazil 4 (11)
Canada 3 (8)
Colombia 2 (6)
Germany 2 (6)
India 6 (17)
Ireland 2 (6)
Israel 2 (6)
Mexico 3 (8)
Paraguay 1 (3)
Philippines 1 (3)
South Africa 2 (6)
Spain 1 (3)
Sweden 1 (3)
Turkey 1 (3)
UK 2 (6)
*USA divided into regions as defined by the US Census Bureau:
Northeast (Connecticut, Maine, Massachusetts, New Hampshire,
New Jersey, New York, Rhode Island, Pennsylvania and Vermont),
South (Alabama, Arkansas, District of Columbia, Delaware, Florida,
Georgia, Kentucky, Louisiana, Maryland, Mississippi, Oklahoma,
North Carolina, South Carolina, Tennessee, Virginia, Texas and
West Virginia), Midwest (Iowa, Illinois, Indiana, Kansas, Michigan,
Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota
and Wisconsin) and West (Alaska, Arizona, California, Colorado,
Hawaii, Idaho, Montana, New Mexico, Nevada, Oregon, Utah,
Washington and Wyoming).
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Concern over ocular toxicity was the second strongest
predictor of fluoroquinolone use in our study. Forti-
fied antibiotics and in particular fortified vancomycin
are known to cause significant ocular surface toxicity,
such as increasing epithelial defect size or conjunc-
tival injection, which can sometimes be difficult to
distinguish from progression of the corneal infection.
Some have advocated using topical linezolid as an
alternative to vancomycin, which has less toxicity but
still covers resistant organisms including MRSA.9
Interestingly, no one in our survey reported using
linezolid. Our observation that those concerned with
broad-spectrum coverage were more likely to choose
fortified antibiotics and those favouring a low toxicity
profile were more likely to choose a single agent
could be influenced by the availability of particular
antibiotics.
Fluoroquinolone antibiotics penetrate ocular tissues
well and have good safety profiles with minimal toxicity
to the ocular surface. They also exhibit broad coverage
of bacterial organisms implicated in bacterial ulcers.
The primary target of fluoroquinolones is DNA gyrase,
an essential bacterial enzyme. There is reason to believe
that because of this mechanism of action, they may be
more susceptible to the development of resistance than
other antibiotics.11 Rates of MRSA infection have been
increasing in North America, and ocular isolates in the
USA have been reported to be resistant to fluoroquino-
lones approximately 80% of the time.12–14 In our study
concern for antibiotic resistance and broad spectrum
coverage were highly predictive of choosing fortified
vancomycin after controlling for location. The fact that
international cornea specialists both have a lower
threshold for MRSA coverage and are less likely to be
using fortified antibiotics suggests that they consider the
prevalence of MRSA to be relatively low in their
population.
The strengths of this study include the geographic
diversity of respondents, providing both US and inter-
national perspectives and representing a broad range
of experience. In addition, a large number of our
respondents were experienced physicians and seeing
ulcers frequently in clinical care. Limitations include
the fact that we only surveyed members of the Cornea
Society listserv, therefore our results may not be gener-
alisable to all ophthalmologists. Additionally the survey
did not ask respondents about their practice setting,
which may be related to empirical antibiotic choice
since those in academic settings may have more access
to fortified antibiotics. Another limitation would be the
multiple-choice format of our question about antibiotic
Figure 2 Graph showing antibiotic choice of US and international cornea specialists for empirical treatment of bacterial
keratitis.
Table 2 Threshold for empirical methicillin-resistant
Staphylococcus aureus coverage (MRSA). Percentage of
MRSA in the community necessary to change the default
corneal ulcer treatment to include MRSA coverage.
% MRSA USA, N
(%)
International,
N (%)
p Value
5%–15% 14 (14) 15 (42) p<0.001
15%–30% 30 (29) 7 (19)
30%–50% 6 (6) 5 (14)
>50% 7 (7) 1 (3)
Default MRSA
coverage
46 (45) 8 (22)
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preference because other options such as vancomycin
monotherapy were not listed (in this case, we listed
vancomycin only in conjunction with other antibiotics
because it only covers Gram-positive bacteria). We
attempted to address this by giving respondents the
option to write in their own preferred antibiotic, but it
is possible the question format affected responses
given.
Practice patterns for the initial treatment of bacterial
keratitis vary with clinicians in the USA more likely to
use fortified antibiotics versus fluoroquinolone mono-
therapy and more concerned with resistant organisms
than their international peers. These differences may
be due to multiple factors, including varying preva-
lence of resistant organisms, lack of availability of
fortified antibiotics and concerns for ocular toxicity.
Determining which of these factors impact clinical
outcomes, such as visual acuity, should be an important
focus of future research.
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